In an announcement released on the ASX, Cann Group has plans to move forward with Phase III clinical trials for their cannabis-based Satipharm CBD capsules, with the aim of ‘securing an approval by the end of calendar year 2022’. As far as we’re aware, no other company has announced time frames for getting the first … Continue reading Cann Group (ASX: CAN) aiming for over-the-counter CBD approval in late 2022